Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Blended Water Supplies Impact Water Treatment

Where does my water come from? The source(s) of water supplied to cooling towers, boilers, and processes may vary greatly daily or even hourly. The impact this has on water systems must be closely monitored to avoid scale, deposits, corrosion, inefficient water usage, and other negative impacts on operational costs. The New York City water…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Where does my water come from?

The source(s) of water supplied to cooling towers, boilers, and processes may vary greatly daily or even hourly. The impact this has on water systems must be closely monitored to avoid scale, deposits, corrosion, inefficient water usage, and other negative impacts on operational costs.

The New York City water supply is a good example, providing over 1.2 billion gallons/day of domestic water to more than 8 million NYC residents, 1 million users from 4 upstate counties, and the city’s many visitors. The water system is made up of aqueducts, distribution pipes, reservoirs, and water tunnels offering a total system storage capacity of close to 550 billion gallons. There are three separate systems that bring water from upstate to the city to fit this need; the Croton, to the east of the Hudson River, and the Catskill and Delaware on the west.

What is in my water?

Since the opening of the Croton Water Filtration facility in May of 2015 water treatment professionals across the five boroughs have faced issues with a blended water supply. The neighborhoods of New York City often receive a combination of all three water supplies, the Croton, Catskill, and Delaware. Operational decisions about the City’s water supply, including the proportion of water from each of the systems, are often made on an hourly basis, creating a constantly changing chemistry of a building’s incoming water.

There is currently no formal notification system in place as to when a change in water supply might occur or what the blend could consist of. When Croton water is introduced to the system there could be areas within the same borough that are 100% Croton water or 100% Catskill/Delaware water, and others that are blended at varying percentages. Conductivity measurements are relied upon to gain an understanding of what water source you’re dealing with at each location throughout the city.

In general, the conductivity of the Catskill/Delaware supply is in the 90-100 µmho range while the conductivity of the Croton water is consistently in the 350-500 µmho range. For many facilities, when the make-up water has a conductivity greater than 100, it is assumed some level of blending is taking place. The chart below details some key differences in the inorganic chemistry of the water supplies:

How does this affect my water treatment?

From a water treatment perspective, fluctuating supply/makeup water sources present significant issues for system control. To understand this concept, it’s important to understand cycles of concentration (COC). Cooling tower cycles are typically controlled by the conductivity of the water in the system. When the conductivity reaches a predetermined set point, the controller bleeds water from the system and replaces it with fresh makeup water. The makeup water has a lower concentration of salts and dilutes the system water. With consistent makeup water, this control method is simple and quite effective because water treatment professionals can predict the levels of dissolved solids in the system water (important for inhibitor choice), determine hold times (the length of time the water stays in the system), and estimate water use.

Cooling tower treatment, for example, commonly bases the cycles of concentration calculation upon conductivity readings. The incoming city water conductivity is multiplied by the targeted number of cycles to use as the conductivity set point. Over-cycling could lead to issues with scale deposition when the concentration of dissolved solids gets above the saturation point. Under-cycling can lead to unnecessary water use, lower operational efficiency, and depending on control method, inaccurate inhibitor residuals. A constantly changing water supply makes it almost impossible to consistently maintain the targeted cycles for a specific system. This is particularly true when there is no way of knowing what type of water you could be receiving at a facility at any given time. Changing the chemistry of the makeup water also changes the target cycles. A varying water supply requires consistent on-site testing of the makeup water and an experienced water treatment professional to effectively manage the fluctuating conditions.

Chem-Aqua has the perfect blend of expertise and experience to manage your changing water demands. Contact a local representative today to review your water treatment program.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512